Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
Arcturus Therapeutics has offered an early snapshot of its inhaled mRNA therapy’s effects in cystic fibrosis, building its case for a delivery technology designed to …
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
KING OF PRUSSIA, Pa. and SAN DIEGO, May 20, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (Nasdaq: ARCT) today announce Nature Communications has published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT, 154, a novel self-amplifying (sa-mRNA) COVID-19 vaccine and the world's first approved sa-mRNA COVID-19 vaccine.
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024